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Background & objectives: AIDS and its associated gastrointestinal complications may impair the absorption
of anti-tuberculosis (TB) drugs. Impaired absorption of anti-TB drugs could lead to low drug exposure,
which might contribute to acquired drug resistance and reduced effectiveness of anti-TB treatment. The
aim of this study was to obtain information on the status of absorption of rifampicin (RMP) and isoniazid
(INH) in asymptomatic HIV- positive individuals, who are less immunocompromised. The D-xylose
absorption test was also carried out to assess the absorptive capacity of intestive.
Methods: The absorption of RMP, INH and D-xylose was studied in 15 asymptomatic HIV- positive
individuals with CD4 cell counts > 350 cells/mm3 and 16 healthy volunteers, after oral administration of
single doses of RMP (450 mg),  INH (300 mg) and D-xylose (5 g). Urine was collected up to 8 h after drug
administration. Percentage dose of the drugs and their metabolites and D-xylose excreted in urine were
calculated.
Results: A significant reduction in the urinary excretion of INH and D-xylose in HIV-positive persons
compared to healthy volunteers was observed.  The per cent dose of RMP and its metabolite, desacetyl
RMP was also lower in HIV-positive persons compared to healthy volunteers, but this difference was not
statistically significant.
Interpretation & conclusion: Decreased urinary excretion of D-xylose and INH are suggestive of intestinal
malabsorption in HIV-positive individuals. HIV infection could cause malabsorption of anti-TB drugs
even at an early stage of the disease. The clinical implications of these findings need to be confirmed in
larger studies.
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Response to rifampicin (RMP) - based
antimycobacterial therapy is generally good in HIV-
infected patients with tuberculosis (TB)1. It has, however,
been widely reported that AIDS and its associated
gastrointestinal complications may impair the absorption
of anti-TB drugs. Decreased absorption of anti-TB drugs
in an HIV-infected patient was reported as early as 19922.
Since that time, several investigators have documented
poor bioavailability of anti-TB drugs in HIV-infected
patients with and without TB3-7. Others have reported
normal absorption in HIV infection8-10. Impaired
absorption of anti-TB drugs could lead to low drug
exposure, which might contribute to acquired drug
resistance and reduced effectiveness of anti-TB
treatment11.  A significant correlation between the degree
of immune suppression and malabsorption has been
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reported by Keating et al12. We have earlier reported a
significant degree of malabsorption of anti-TB drugs
among patients with advanced HIV disease, with and
without diarrhoea. These findings were based on both
blood5 and urine4 levels of anti-TB drugs. We extended
our study to obtain information on the status of absorption
of RMP and isoniazid (INH) in asymptomatic HIV-
positive individuals, who are less immunocompromised,
by measuring the urinary excretion of these drugs. The
D-xylose absorption test to assess the absorptive capacity
of the intestines was also performed.
Material & Methods
Participants: Sixteen healthy volunteers, willing staff
members working at Tuberculosis Research Centre,
Chennai and not known to be seropositive for HIV
infection and 15 HIV seropositive asymptomatic persons
participated in the study. Eligible HIV-positive
individuals were selected from those attending the
outpatient clinic of the Tuberculosis Research Centre,
between June to September 2005. Asymptomatic
persons were classified as having stage I A or II A
infection as defined by the Centers for Disease Control
and Prevention classification system, 199313. The sample
size was chosen based on the study findings reported
by Agarwal et al14. All study participants were males
and were required to meet the following criteria: (i) age
18-50 yr, (ii) no significant hepatic or renal dysfunction
(liver transaminases, blood urea and creatinine within
normal limits), (iii) non-diabetic, (iv) CD4 cell counts
‡ 350 cells/ml3, (v) not taken RMP or INH for atleast a
month before start of the study, and (vi) willing to give
informed written consent. Diagnosis of HIV infection
was based on 3 positive results (2 rapid tests, Tridot,
Mitra and Co. and Combaids, Span Diagnostics, India
followed by ELISA, Labsystems). None of the HIV
seropositive persons was receiving antiretroviral
treatment. The study was conducted after obtaining
approval from the institutional ethics committee, and
informed written consent was obtained from all the study
participants before they took part in the study.
Conduct of study: Baseline demographic, clinical and
laboratory data were obtained from all eligible study
participants. They were asked to report to the clinic in
the morning after an overnight fast. They were instructed
to empty their bladder and then received RMP (450 mg)
and INH (300 mg) orally under supervision. The exact
time of drug administration was noted. Two hours later, a
uniform oral dose of D-xylose (5 g) in water was
administered. Urine excreted up to 8 h after drug
administration was collected in labeled containers. The
study was conducted under the complete supervision of
the study investigators. Care was taken to ensure that the
urine collections were complete. The volume of urine was
measured and aliquots were stored at -20oC. Ascorbic acid
was added to urine aliquots to prevent oxidation of RMP.
Determination of INH acetylator status: The INH
acetylator status of all the study participants was
determined by differentially estimating the concentrations
of INH and its primary metabolite, acetyl INH (AINH)
in urine excreted between 5 and 6 h after oral
administration of 300 mg INH, and by calculating the
molar ratio of AINH to INH. The acetylator status was
considered to be rapid when the ratio was 2.0 or more15.
Drug estimations: The concentrations of RMP and its
primary metabolite, desacetyl RMP (DRMP) were
measured by high performance liquid chromatography
(HPLC)16. The concentrations of INH and AINH17 and
that of D-xylose18 were measured by spectrophotometric
methods. The values were expressed as percentage dose
of RMP (RMP & DRMP), INH (INH & AINH) and
D-xylose excreted in urine.
Statistical analysis: Analysis of data was performed
using SPSS software package, version 13.0. The mean
percentage doses of D-xylose, RMP and INH excreted
in urine were compared between HIV-positive
individuals and healthy volunteers by independent
t-test. Significance was taken at the 5 per cent level.
Results
There were no significant differences in the mean
age and body weight between HIV-positive individuals
and healthy volunteers (Table I). The mean per cent
doses of D-xylose, and INH and AINH excreted in urine
were significantly lower in HIV-positive individuals
compared to healthy volunteers (Table II). The mean
per cent doses of RMP and  DRMP excreted in urine of
healthy volunteers and HIV-infected individuals were
10.8 and 8.0 per cent respectively, the difference was
not statistically significant. The per cent dose of INH
excreted in urine was calculated, and comparisons were
made between HIV-positive individuals and healthy
volunteers among slow and rapid acetylators separately.
The mean per cent doses of INH among slow acetylators
were 29.6±1.9 per cent in healthy volunteers and
25.5±3.7 per cent in HIV-positive individuals (P<0.05).
The corresponding values among rapid acetylators were
15.2±3.0 per cent and 11.5±3.8 per cent respectively.
The decrease in urinary excretion of INH in HIV-positive
persons compared to healthy volunteers among slow and
rapid acetylators was 14 and 24 per cent respectively.
Table I. Characteristics of study participants and healthy volunteers
Group
Characteristic Healthy Asymptomatic
volunteers HIV-positive
individuals
(n = 16) (n = 15)
Mean age ±SD (yr) 36 ± 9.9(23-52) 32 ± 6.7 (25-50)
Mean body weight ±SD (kg) 63 ± 8.5(48-76) 56 ± 7.5(41-71)
Median CD4 cell 425 (350-853)
count (cells/mm3)
INH acetylator status
(No. of participants)
Slow 8 8
Rapid 8 7
Values are mean ± SD
Ranges are given in parentheses
Table II.  Percentage dose (mean ± SD) of D-xylose, rifampicin and
isoniazid excreted in urine in different  study groups
D-Xylose RMP + DRMP INH + AINH
Healthy volunteers 29.3 10.8 46.0
(n=16) ± ± ±
4.6 5.5 4.2
HIV-positive 23.1** 8.0 40.1*
 individuals ± ± ±
(n = 15) 5.4 2.0 8.3
P * <0.05  **<0.01 compared to healthy volunteers
DRMP,  desacetyl  RMP
AINH, acetyl INH
Discussion
All the HIV-positive individuals who took part in
the study had CD4 cell counts greater than or equal to
350 cells/mm3. Although they were not
immunocompromised, the percentage doses of RMP and
INH excreted in urine were decreased in asymptomatic
HIV-positive individuals when compared to healthy
volunteers. This observation points to the fact that HIV
infection causes malabsorption of anti-TB drugs even
at an early stage of the disease. This is supported by a
study carried out by Knox et al19 who found impaired
absorptive function in 88 per cent of  671 HIV-infected
persons studied. They concluded that gastrointestinal
dysfunction was common among HIV-positive persons,
appeared early in the course of infection, in the absence of
diarrhoea and in persons with CD4 counts >200 cells/mm3.
Our findings are in agreement with that reported
by Sahai et al3, who observed reduction in exposure
and peak concentration of certain anti-TB drugs in
asymptomatic HIV-positive individuals. They observed
a significant and systematic decrease in blood levels
of certain anti-TB drugs when studying healthy
volunteers at one end of the spectrum to symptomatic
HIV patients with diarrhoea at the other end of the
spectrum. When our present data, obtained in
asymptomatic HIV-positive individuals, were
compared with that obtained from our earlier study4
done in symptomatic HIV patients with and without
TB, it was found that the percentage doses of D-xylose,
RMP and INH obtained in this study were between
pulmonary TB patients (control group) and patients
with advanced HIV disease. This suggests that there
is a trend of decreased absorption and urinary excretion
of D-xylose, RMP and INH occurring in HIV-infected
persons as their disease advances, similar to the
observations made by Sahai et al3. Keating et al12,
however, did not observe malabsorption of D-xylose
in asymptomatic HIV-infected persons, but found
increased intestinal permeability in all sub-groups of
patients, and a significant correlation between
malabsorption and degree of immunosuppression. Our
earlier observations20,21  and that of others22, 23 have
pointed to the fact that bioavailability indices of anti-
TB drugs, calculated based on blood and urine levels
are similar. Urine estimations have the added advantage
of being non-invasive and easy to perform. However,
care must be taken to ensure that the urine collections
are complete within the stipulated time periods.
The metabolizing enzyme of INH is a hepatic N-
acetyl transferase, which displays genetic
polymorphism. The difference in the two phenotypes
of this enzyme, namely, slow and rapid acetylators of
INH is due to difference in quantity rather than quality
of the enzyme, the rapid acetylators having 4-5 times
the quantity of the enzyme as the slow acetylators. It is
therefore expected that rapid acetylators will have
enhanced metabolism of INH, and that blood levels and
urinary excretion of INH will be lower in rapid than in
slow acetylators. This observation was confirmed in our
study.
In conclusion, this study demonstrates that HIV
infection, regardless of the stage of the disease may lead
to malabsorption of anti-TB drugs. Clinicians caring for
HIV-positive patients may need to consider assessing
malabsorption in patients with inadequate response/
failure/development of drug resistance. Urine levels of
anti-TB drugs can be monitored in HIV-infected patients.
This is particularly important in those who are slow to
respond to therapy. These findings are also important
because many individuals with HIV infection are started
on preventive therapy for TB with INH or a combination
of two or three anti-TB drugs. One of the reasons for
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failure of preventive therapy may be malabsorption and
inadequate blood levels of anti-TB drugs. Further studies
are required to correlate drug levels and clinical
outcomes both in the treatment and prevention of TB in
HIV-positive individuals.
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